Integrated Process Model Applications Linking Bioprocess Development to Quality by Design Milestones
Authors:
- Christopher TaylorChristopher Taylor
- Lukas MarschallLMLukas Marschall
- Marco KunzelmannMKMarco Kunzelmann
- Michael RichterMRMichael Richter
- Frederik RudolphFRFrederik Rudolph
- Judith VajdaJVJudith Vajda
- Beate PresserBPBeate Presser
- Thomas ZahelTZThomas Zahel
- Joey StudtsJSJoey Studts
- Christoph HerwigChristoph Herwig
Open Access
- 24 October 2021
- journal article
- research article
- Published by MDPI AG in Bioengineering
- Vol. 8 (11) , 156
Abstract
Maximizing the value of each available data point in bioprocess development is essential in order to reduce the time-to-market, lower the number of expensive wet-lab experiments, and maximize process understanding. Advanced in silico methods are increasingly being investigated to accomplish these goals. Within this contribution, we propose a novel integrated process model procedure to maximize the use of development data to optimize the Stage 1 process validation work flow. We generate an integrated process model based on available data and apply two innovative Monte Carlo simulation-based parameter sensitivity analysis linearization techniques to automate two quality by design activities: determining risk assessment severity rankings and establishing preliminary control strategies for critical process parameters. These procedures are assessed in a case study for proof of concept on a candidate monoclonal antibody bioprocess after process development, but prior to process characterization. The evaluation was successful in returning results that were used to support Stage I process validation milestones and demonstrated the potential to reduce the investigated parameters by up to 24% in process characterization, while simultaneously setting up a strategy for iterative updates of risk assessments and process controls throughout the process life-cycle to ensure a robust and efficient drug supply.Keywords
This publication has 14 references indexed in Scilit:
- Modeling in the quality by design environment: Regulatory requirements and recommendations for design space and control strategy appointmentInternational Journal of Pharmaceutics, 2017
- Integrated Process Modeling—A Process Validation Life Cycle CompanionBioengineering, 2017
- Statistical Approaches to Assess Biosimilarity from Analytical DataThe AAPS Journal, 2016
- Risk evaluation approaches in failure mode and effects analysis: A literature reviewExpert Systems with Applications, 2013
- Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein: Towards a global multi‐step design spaceJournal of Pharmaceutical Sciences, 2012
- Defining process design space for monoclonal antibody cell cultureBiotechnology and Bioengineering, 2010
- The ICH Q8 Definition of Design Space: A Comparison of the Overlapping Means and the Bayesian Predictive ApproachesStatistics in Biopharmaceutical Research, 2010
- Product and process innovation in biopharmaceuticals: a new perspective on developmentR&D Management, 2006
- Integration of FMEA and the Kano modelInternational Journal of Quality & Reliability Management, 2004
- A new approach for evaluation of risk priorities of failure modes in FMEAInternational Journal of Production Research, 2001